A broader lens on tuberculosis cost-effectiveness analysis: How patient-incurred costs and post-tuberculosis outcomes reshape estimates in a multi-country study.

ABSTRACT: Tuberculosis (TB) remains a major public health challenge, with financial and health impacts extending beyond treatment. Both the perspective adopted in cost-effectiveness analyses-which critically determines choices such as the inclusion of patient-incurred costs-and the extent to which long-term post-treatment considerations are incorporated have important policy implications. This study examines how the choice of timeframe and cost perspectives influence the estimated cost-effectiveness of TB interventions, particularly preventative measures. Using data from 19 WHO TB patient cost surveys and global epidemiological databases, we modelled a hypothetical preventative TB intervention, generating four incremental cost-effectiveness ratios (ICERs) per country under different analytical appro

SUBMITTER: Tomeny EM 

PROVIDER: S-EPMC12425205 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature